Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Mekonos

Mekonos

Mekonos is a company that creates cell-engineering platforms

Mekonos is a company that has created a platform that allows cell and gene therapies to be more accessible. The company was founded by Anil Narsimha, Greg Sitters, and Steven Banerjee in 2017, in San Francisco, California, United States.

Mekonos is responsible for developing over nine hundred therapeutic candidates, and expect roughly forty of them to be approved by the end of 2022. They developed their therapeutics through their platform solution, Iris, which is a System-on-a-Chip that allows for automated deliveries and precision for multiplexing.

Iris is a pharmaceutical and biotechnological platform that allows for targeted delivery and dose control of gene therapeutics that includes nucleic acids, protein complexes, and small molecules, and cell treatments such as primary, immune, and stem cells.

Microfluidics, micro-electro-mechanical systems, and chemistry to expand their catalogue of payloads and cell types. Their various methods of expansion allows Mekonos to scale their silicon technology for drug discover and development.

Timeline

November 10, 2021
Mekonos raises a $25,000,000 series A round.

Funding rounds

Patents

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

News

Title
Author
Date
Publisher
Description
Mekonos
November 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- Mekonos, a biotech company launching the first-of-its kind system-on-a-chip (SoC) for targeted ex vivo gene engineering, today announced it has...

References

Golden logo
By using this site, you agree to our Terms & Conditions.